Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Full Year 2019 Xvivo Perfusion AB Earnings Call Transcript

Jan 30, 2020 / 01:00PM GMT
Release Date Price: kr174 (-8.42%)
Operator

Ladies and gentlemen, welcome to the XVIVO Perfusion report webcast.

I will now hand over to Magnus Nilsson, CEO. Sir, please go ahead.

Magnus Nilsson;publ;CEO
Xvivo Perfusion AB

()-

Thank you very much. I have on my side, Christoffer Rosenblad, hello, and I'd like to take you through a presentation of the interim report of 2019, the 29th quarterly report. I have to excuse myself for having a cold here, so I hope you -- my voice comes through.

Right. Slide #2. We have had a historic year 2019, which ended with a record quarter, something everyone hasn't really appreciated, I think. But anyways, in Q4, we had a breakthrough designation in the -- with the FDA for the heart preservation system, something that would speed up the process in the U.S.

We have started up an Australian subsidiary, which was established then after the third of 4 possible XPS installations and also in preparation for our clinical trial in Australia.

During the full year, we had our first PMA, the first for such a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot